Drug-Drug Interaction
Conditions
Keywords
lorecivivint, triamcinolone acetonide
Brief summary
This study will be an open-label, parallel-arm study to determine if a prior intra-articular (IA) injection of lorecivivint (LOR) affects the safety, tolerability, and/or pharmacokinetics (PK) of a subsequent IA injection of the corticosteroid triamcinolone acetonide (TA) into the same knee, and to determine if a prior IA injection of TA affects the safety or tolerability of a subsequent IA injection of LOR into the same knee.
Interventions
DRUGLorecivivint (LOR)
0.07 mg
40 mg
Sponsors
Biosplice Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: 1. Males and females between 18 and 55 years of age, inclusive, in general good health 2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at Screening 3. Negative drug test for amphetamine, cocaine, methadone, opiates, phencyclidine (PCP), barbiturates, benzodiazepines, tricyclic antidepressants, and marijuana Key
Exclusion criteria
1. Pregnant women, breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) who have a positive or indeterminate pregnancy test result at the Screening Visit or Day -1 2. Women who are not post-menopausal or permanently surgically sterile who are sexually active, and who are not willing to use birth control during the study period 3. Men who are sexually active and of reproductive potential, who have partners who are capable of becoming pregnant, and who are not willing to use birth control during the study period 4. Any chronic medical condition that requires medication 5. Any history of IA injection, surgery (e.g., arthroscopy), infection, major orthopedic injury, or inflammatory rheumatic diseases (e.g., rheumatoid arthritis, gout, pseudogout) of either knee 6. Any contraindications for an IA injection in the right knee in the opinion of the Investigator 7. Previous treatment with lorecivivint (LOR) 8. Treatment with any glucocorticoids (oral, intravenous, intramuscular, IA, topical, or inhaled) within 12 weeks before Day 1 9. Consumption of grapefruit, grapefruit juice, Seville oranges, or vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts) within 10 days before Day 1 10. Known hypersensitivity to triamcinolone acetonide (TA) 11. Significant blood loss (\> 500 mL) or donation of blood within 30 days of screening 12. Regular use of nicotine-containing products, including, but not limited to, cigarettes, e-cigarettes, or nicotine gum or patches 13. Any condition, that, in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation 14. Estimated glomerular filtration rate (eGFR) of \< 60 mL/min/1.73 m2, calculated using the Modification of Diet in Renal Disease (MDRD) equation at the Screening Visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax of LOR | 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration |
| AUC 0-last of LOR | 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration |
| Plasma concentration profiles of LOR | 0, 0.25, 0.5, 1, 2, 4, 6, 8 hours after administration |
| Cmax of TA | 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration |
| AUC 0-last of TA | 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration |
| Plasma concentration profiles of TA | 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 96 hours after administration |
Countries
United States
Outcome results
None listed